Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracochlear Triamcinolone Acetonide in Sudden Sensorineural Hearing Loss
2024-513145-36-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of triamcinolone acetonide in acute sensorineural hearing loss (2 arms), sponsored by Medical University of Vienna. Planned start Dec 2024; status: authorised.
02
Drugs
triamcinolone acetonide
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on 2024-513145-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513145-36-00.